LONDON and NEW YORK—Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to patients with sight-threatening eye diseases, announced several appointments to its executive team. The company also announced details on Restoret, the first asset in a diversified pipeline of multi-specific agonist antibodies. Restoret is a tri-specific Wnt agonist antibody designed to address medical needs in patients with back-of-the-eye diseases. “We founded EyeBio to capture scientific advances and translate them into effective treatments for patients with serious eye diseases,” said David Guyer, MD, co-founder, CEO, and president of EyeBio.

“The world-class team we have assembled gives us the talent and resources to continue our rapid progress and success in advancing a strong pipeline. It is a privilege to be surrounded by an elite group of leaders in ophthalmology, many of whom have been working in this space since the dawn of pharmacotherapy for eye disease.”

EyeBio announced the following appointments to the senior leadership team:

Anthony P. Adamis, MD, has been appointed chief scientific officer. Dr. Adamis, who co-founded EyeBio in 2021 and Eyetech in 2002 with Dr. Guyer, previously served as senior vice president of product development and development innovation at Genentech. Over the course of his career, he has led development programs in multiple therapeutic areas and has overseen 25 U.S. Food and Drug Administration (FDA) approvals.

“EyeBio is building one of the strongest ophthalmology pipelines in biopharma: Two novel and innovative agonist antibody assets, both with first-in-class and best-in-class potential,” said Dr. Adamis. “I am delighted to join a company that can combine such scientific potential with a global team of highly experienced ophthalmic drug developers.”

In addition to Dr. Adamis, EyeBio announced senior leadership appointments that further expand its international team of executives and investors with a track record for developing ophthalmology therapies:

  • Loni Da Silva, chief regulatory officer, brings extensive ophthalmology regulatory leadership experience and led the first retinal drug approval (Macugen).

  • Frances Betts, global head, clinical operations, has recruited thousands of patients into more than 20 ophthalmology clinical trials.

  • Mike Davies, chemistry, manufacturing, and control (CMC) lead, drug development, led protein sciences for the development of bispecific antibodies at F-Star Therapeutics.

  • Eric Ng, PhD, senior vice president, biology, developed novel therapeutics and animal models in ophthalmology as an associate professor at Harvard University.